HCV NS5B polymerase inhibitor nucleotide derivatives (Longwood Biopharmaceuticals)

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug NameHCV NS5B polymerase inhibitor nucleotide derivatives (Longwood Biopharmaceuticals)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives
Mechanisms of ActionHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors
TargetsHepatitis C virus NS5B RNA-dependent RNA polymerase
Therapy Area/IndicationsHepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesLongwood Biopharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLongwood Biopharmaceuticals Ltd
Inactive CompaniesN/A
Active IndicationsHepatitis C
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A